Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
185actual
Sites
12
Countries
Egypt, Jordan, Lebanon +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-15 | actual | When the study began enrolling |
| Primary completion | 2025-04-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-29 | actual | The whole study's end, after follow-up |
| First posted | 2021-06-24 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Breast Cancer
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Who Were Progression Free at 6 Months Post Palbociclib Initiation
measured At 6 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 12 Months Post Palbociclib Initiation
measured At 12 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 18 Months Post Palbociclib Initiation
measured At 18 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 24 Months Post Palbociclib Initiation
measured At 24 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Alive at 1 Year Post Palbociclib Initiation
measured At 1 year from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Alive at 2 Years Post Palbociclib Initiation
measured At 2 year from the date of palbociclib initiation in routine clinical practice
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-11-08 · 1.9 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-02-15 · 3.2 MB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed